GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » 10-Year Sharpe Ratio

XOMA Royalty (STU:X0M1) 10-Year Sharpe Ratio : 0.23 (As of Jul. 06, 2025)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-07-06), XOMA Royalty's 10-Year Sharpe Ratio is 0.23.


Competitive Comparison of XOMA Royalty's 10-Year Sharpe Ratio

For the Biotechnology subindustry, XOMA Royalty's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's 10-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's 10-Year Sharpe Ratio falls into.


;
;

XOMA Royalty 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.


XOMA Royalty  (STU:X0M1) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


XOMA Royalty 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

XOMA Royalty Headlines

No Headlines